|
|
|
|
| LEADER |
02686nam a2200373 u 4500 |
| 001 |
EB001897068 |
| 003 |
EBX01000000000000001060073 |
| 005 |
00000000000000.0 |
| 007 |
tu||||||||||||||||||||| |
| 008 |
200523 r ||| eng |
| 100 |
1 |
|
|a Clark, Michelle
|
| 245 |
0 |
0 |
|a Management of acute withdrawal and detoxification for adults who misuse methamphetamine
|h Elektronische Ressource
|b a review of the clinical evidence and guidelines
|c Michelle Clark, Robin Featherstone
|
| 246 |
3 |
1 |
|a Management of acute withdrawal and detoxification for adults who misuse methamphetamines
|
| 250 |
|
|
|a Version 1.0
|
| 260 |
|
|
|a Ottawa
|b CADTH
|c 2019, February 08, 2019
|
| 300 |
|
|
|a 1 PDF file (28 pages)
|b illustrations
|
| 505 |
0 |
|
|a Includes bibliographical references
|
| 653 |
|
|
|a Amphetamine-Related Disorders / drug therapy
|
| 653 |
|
|
|a Canada
|
| 653 |
|
|
|a Anti-Anxiety Agents / therapeutic use
|
| 653 |
|
|
|a Methamphetamine / adverse effects
|
| 653 |
|
|
|a Substance Withdrawal Syndrome / drug therapy
|
| 653 |
|
|
|a Antihypertensive Agents / therapeutic use
|
| 653 |
|
|
|a Treatment Outcome
|
| 653 |
|
|
|a Antipsychotic Agents / therapeutic use
|
| 653 |
|
|
|a Practice Guidelines as Topic
|
| 700 |
1 |
|
|a Featherstone, Robin
|e [author]
|
| 710 |
2 |
|
|a Canadian Agency for Drugs and Technologies in Health
|b Rapid Response Service
|
| 041 |
0 |
7 |
|a eng
|2 ISO 639-2
|
| 989 |
|
|
|b NCBI
|a National Center for Biotechnology Information
|
| 490 |
0 |
|
|a CADTH rapid response report: summary with critical appraisal
|
| 856 |
4 |
0 |
|u https://www.ncbi.nlm.nih.gov/books/NBK545066
|3 Volltext
|n NLM Bookshelf Books
|3 Volltext
|
| 082 |
0 |
|
|a 610
|
| 520 |
|
|
|a Methamphetamine is a highly addictive drug that is created illegally in clandestine laboratories using a variety of household chemicals, including ephedrine or pseudoephedrine, that is extracted from over the counter medications. There is no legally available alternative drug. Methamphetamine comes as a white powder or a crystal format and can be sniffed up the nose or mixed with water and injected. The production of methamphetamine is dangerous and produces large volumes of toxic chemical waste. In 2006, Canada introduced new regulations to limit access to the precursor chemicals needed to produce methamphetamine including the move to keep ephedrine-containing products behind the pharmacy counter. The prevalence of methamphetamine use in Canada is low, with about 0.2% of the population reported to use the substance; however, it would appear that the availability of methamphetamine in Canada has recently increased. There was a 590% increase in the number of methamphetamine-related drug offences and seizures between 2010 and 2017
|